1
|
Mone P, Izzo R, Marazzi G, Manzi MV, Gallo P, Campolongo G, Cacciotti L, Tartaglia D, Caminiti G, Varzideh F, Santulli G, Trimarco V. L-Arginine Enhances the Effects of Cardiac Rehabilitation on Physical Performance: New Insights for Managing Cardiovascular Patients During the COVID-19 Pandemic. J Pharmacol Exp Ther 2022; 381:197-203. [PMID: 35339987 DOI: 10.1124/jpet.122.001149] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 03/21/2022] [Indexed: 11/22/2022] Open
Abstract
Cardiac rehabilitation (CR) following acute myocardial infarction (AMI) improves physical capacities and decreases hospitalizations and cardiovascular mortality. L-Arginine is the substrate used by nitric oxide (NO) synthase (NOS) to generate NO and it has been shown to exert its beneficial effects on endothelium driving vasodilatation, reducing inflammation, and ameliorating physical function. We hypothesized that L-Arginine could enhance physical capacities in patients who underwent CR after AMI. We designed a study aimed to assess the effects of L-arginine administration on the physical capacity of patients who underwent coronary revascularization after AMI. The trial was carried out amid the COVID-19 pandemic. Patients were assigned, with a 2:1 ratio, to add to their standard therapy 1 bottle containing 1.66 g of L-arginine or 1 bottle of identical aspect apart from not containing L-arginine, twice a day orally for 3 weeks. Patients performed a 6-minute walking test (6MWT) and were assessed their Borg modified 0-10 rating of perceived exertion (BRPE) before starting and at the end of the treatment. Seventy-five patients receiving L-Arginine, and thirty-five receiving placebo successfully completed the study. The 6MWT distance increased significantly in the L-Arginine group compared to both baseline and placebo (p<0.0001). Additionally, we observed a significant improvement in the BRPE in patients treated with L-arginine but not in the placebo group. Taken together, our data indicate that L-arginine potentiates the response to CR, independently of age, sex, baseline functional capacity, and comorbid conditions. Significance Statement This study shows for the first time that oral supplementation of L-arginine potentiates the response to cardiac rehabilitation after myocardial infarction and cardiac revascularization. Indeed, we observed a significant improvement in two fundamental parameters, namely, the 6-minute walking test and the Borg modified 0-10 rating of perceived exertion. Strikingly, the beneficial effects of L-arginine were independent from age, sex, comorbid conditions, and baseline functional capacity.
Collapse
|
2
|
Bernocchi P, Vitacca M, La Rovere MT, Volterrani M, Galli T, Baratti D, Paneroni M, Campolongo G, Sposato B, Scalvini S. Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial. Age Ageing 2018; 47:82-88. [PMID: 28985325 DOI: 10.1093/ageing/afx146] [Citation(s) in RCA: 93] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 07/31/2017] [Indexed: 12/30/2022] Open
Abstract
Background chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) frequently coexist in older people, reducing patients' quality of life (QoL) and increasing morbidity and mortality. Objective we studied the feasibility and efficacy of an integrated telerehabilitation home-based programme (Telereab-HBP), 4 months long, in patients with combined COPD and CHF. The primary outcome was exercise tolerance evaluated at the 6-min walk test (6MWT). Secondary outcomes were time-to-event (hospitalisation and death), dyspnoea (MRC), physical activity profile (PASE), disability (Barthel) and QoL (MLHFQ and CAT). Study design randomised, open, controlled, multicenter trial. Methods the Telereab-HBP included remote monitoring of cardiorespiratory parameters, weekly phone-calls by the nurse, and exercise programme, monitored weekly by the physiotherapist. All outcomes were studied again after 2 months of a no-intervention period. Results in total, 112 patients were randomised, 56 per group. Their mean (SD) age was 70 (9) years, and 92 (82.1%) were male. After 4 months, the IG were able to walk further than at baseline: mean (95% CI) Δ6MWT was 60 (22.2,97.8) m; the CG showed no significant improvement: -15 (-40.3,9.8) m; P = 0.0040 between groups. In IG, the media time to hospitalisation/death was 113.4 days compared with 104.7 in the CG (P = 0.0484, log-rank test). Other secondary outcomes: MRC (P = 0.0500), PASE (P = 0.0015), Barthel (P = 0.0006), MLHFQ (P = 0.0007) and CAT (P = 0.0000) were significantly improved in the IG compared with the CG at 4 months. IG maintained the benefits acquired at 6 months for outcomes. Conclusions this 4-month Telereab-HBP was feasible and effective in older patients with combined COPD and CHF.
Collapse
Affiliation(s)
- Palmira Bernocchi
- Care Continuity Unit and Telemedicine Service, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy
| | - Michele Vitacca
- Respiratory Rehabilitation Division, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy
| | - Maria Teresa La Rovere
- Cardiac Rehabilitation Division, Istituti Clinici Scientifici Maugeri IRCCS, Montescano, Pavia,
Italy
| | | | - Tiziana Galli
- Respiratory Rehabilitation Division, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy
| | - Doriana Baratti
- Care Continuity Unit and Telemedicine Service, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy
| | - Mara Paneroni
- Respiratory Rehabilitation Division, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy
| | | | - Barbara Sposato
- Cardiology Department, San Raffaele Pisana IRCCS, Roma, Italy
| | - Simonetta Scalvini
- Care Continuity Unit and Telemedicine Service, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy
- Cardiac Rehabilitation Division, Istituti Clinici Scientifici Maugeri IRCCS, Lumezzane, Brescia, Italy
| |
Collapse
|
3
|
Fossati C, Volterrani M, Punzo N, Campolongo G, Cascelli G, Caminiti G. Dose-dependent effects of ivabradine on heart rate during maximal efforts in a woman with permanent atrial fibrillation. Int J Cardiol 2017; 247:37. [PMID: 28916075 DOI: 10.1016/j.ijcard.2017.04.071] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Accepted: 04/20/2017] [Indexed: 11/16/2022]
Affiliation(s)
- Chiara Fossati
- Department of Medical Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, Rome, Italy; Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", Piazza Lauro de Bosis 15, Rome, Italy
| | - Maurizio Volterrani
- Department of Medical Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, Rome, Italy
| | - Noemi Punzo
- Department of Medical Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, Rome, Italy
| | - Giuseppe Campolongo
- Department of Medical Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, Rome, Italy
| | - Giovanna Cascelli
- Department of Medical Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, Rome, Italy
| | - Giuseppe Caminiti
- Department of Medical Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, Rome, Italy.
| |
Collapse
|
4
|
Marazzi G, Campolongo G, Pelliccia F, Quattrino S, Vitale C, Cacciotti L, Massaro R, Volterrani M, Rosano G. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). Am J Cardiol 2017; 120:893-897. [PMID: 28781026 DOI: 10.1016/j.amjcard.2017.06.015] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Revised: 05/19/2017] [Accepted: 06/07/2017] [Indexed: 01/21/2023]
Abstract
Low-density lipoprotein cholesterol (LDL-C) reduction is associated with a significant decrease in mortality, and statins represent the most effective drugs to achieve this. However, side effects of statins are very common and may lead to treatment discontinuation. Nutraceuticals are a combination of natural components that have shown efficacy in lowering LDL-C concentration when used alone or in association with other agents in patients who are intolerant to high-dose statins. Our aim was to compare the efficacy and tolerability of low-dose statin (LDS) therapy versus combined therapy of LDS plus a nutraceutical combination containing red yeast rice, policosanol, berberine, folic acid, coenzyme Q10 and astaxanthin (Armolipid Plus) in high-risk patients. We performed a randomized (1:1), prospective, parallel group, single-blind trial in which participants had coronary artery disease (n = 100), had undergone percutaneous coronary intervention in the preceding 12 months, were high-dose statin intolerant, and did not achieve ≥50% reduction in LDL-C with LDS treatment alone. After 3 months, patients in the LDS + Armolipid Plus (n = 50) group presented with a significantly greater reduction of LDL-C and total cholesterol (p <0.0001), and 70% of patients in this group achieved the therapeutic target (LDL-C <70 mg/dl), whereas patients in the LDS group did not. Six patients (3 from each group) dropped out due to myalgia. In conclusion, in patients with coronary artery disease and high-dose statin intolerance, the combination of LDS and nutraceuticals represents a valuable therapeutic option.
Collapse
Affiliation(s)
- Giuseppe Marazzi
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy.
| | - Giuseppe Campolongo
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | | | - Silvia Quattrino
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | - Cristiana Vitale
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | - Luca Cacciotti
- Institute of Cardiology, Madre Giuseppina Vannini Hospital, Rome, Italy
| | - Rosalba Massaro
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | - Maurizio Volterrani
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | - Giuseppe Rosano
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| |
Collapse
|
5
|
Cangemi R, Romiti GF, Campolongo G, Ruscio E, Sciomer S, Gianfrilli D, Raparelli V. Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: The never-ending debate. Pharmacol Res 2017; 117:148-155. [DOI: 10.1016/j.phrs.2016.12.027] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Revised: 11/21/2016] [Accepted: 12/20/2016] [Indexed: 02/08/2023]
|
6
|
Marazzi G, Pelliccia F, Campolongo G, Cacciotti L, Massaro R, Poggi S, Tanzilli A, Di Iorio M, Volterrani M, Lainscak M, Rosano GM. Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: The ALL-IN-ONE trial. Int J Cardiol 2016; 222:885-887. [PMID: 27522394 DOI: 10.1016/j.ijcard.2016.07.163] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 07/27/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND The ultimate goal of antihypertensive therapy is cardiovascular risk (CVR) reduction. The aim of this study was to compare the efficacy and safety of once-daily fixed combination (ODFC) versus free-drug combination (FDC) of 3antihypertensive agents and statin. METHODS The ALL-IN-ONE trial was a 12-week randomized, prospective, multicenter trial. A total of 305 hypertensive patients were randomized 1:1. The "fixed group" was given an ODFC of perindropil 10mg plus indapamide 2.5mg plus amlodipine 5 or 10mg plus atorvastatin 20mg. The "free group" was given a FDC of the 3antihypertensive agents plus atorvastatin 20mg. Primary end-points were the differences in clinic BP, cholesterol levels and CVR risk between the 2 groups after treatments. Secondary end-points included intragroup differences in clinic BP. Safety and compliance were also assessed. RESULTS At 12-weeks, the fixed group had lower systolic BP and similar diastolic BP compared to the free group. BP targets at week 12 were more commonly reached with fixed than free combination (89% and 80% respectively, p=0.048). For cholesterol serum in both groups there was a significant reduction of values. Also CVR reduction was greater in those taking ODF. Safety was not significantly different between the 2 groups. Conversely, compliance was significantly greater in the fixed-group vs. the free-group. CONCLUSION This randomized trial shows that ODF combination of perindropil, indapamide and amlodipine is as safe as free combination of the 3 drugs, but is associated with a greater efficacy in BP control, compliance and, associated with statin, in cholesterol reduction. A better cardiovascular risk control is achieved with ODF combination than with a free administration. ClinicalTrials.gov ID: NCT02710539.
Collapse
Affiliation(s)
| | | | | | | | | | - Sara Poggi
- Sapienza University of Rome, 1st Faculty of Medicine, Rome, Italy
| | | | - Martina Di Iorio
- Sapienza University of Rome, 1st Faculty of Medicine, Rome, Italy
| | | | | | | |
Collapse
|
7
|
Campolongo G, Riccioni CV, Raparelli V, Spoletini I, Marazzi G, Vitale C, Volterrani M. The combination of nutraceutical and simvastatin enhances the effect of simvastatin alone in normalising lipid profile without side effects in patients with ischemic heart disease. ACTA ACUST UNITED AC 2016. [DOI: 10.1016/j.ijcme.2016.03.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
8
|
Marazzi G, Pelliccia F, Campolongo G, Quattrino S, Cacciotti L, Volterrani M, Gaudio C, Rosano G. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. Am J Cardiol 2015; 116:1798-801. [PMID: 26611120 DOI: 10.1016/j.amjcard.2015.09.023] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 09/15/2015] [Accepted: 09/15/2015] [Indexed: 12/20/2022]
Abstract
Statins are extensively used to treat dyslipidemia, but, because of their low tolerability profile, they are discontinued in a significant proportion of patients. Ezetimibe and nutraceuticals have been introduced as alternative therapies and have proved to be effective and well tolerated. A single-blind, single-center, randomized, prospective, and parallel group trial comparing a combination of nutraceuticals (red yeast rice, policosanol, berberine, folic acid, coenzyme Q10 and astaxanthin), called Armolipid Plus, and ezetimibe for 3 months in terms of efficacy and tolerability. Patients who did not achieve their therapeutic target (low-density lipoprotein cholesterol <100 mg/dl) could add the alternative treatment on top of randomized treatment for another 12 months: 100 patients who are dyslipidemic with ischemic heart disease treated with percutaneous coronary intervention were enrolled (ezetimibe n = 50, nutraceutical n = 50). Efficacy (lipid profile) and tolerability (adverse events, transaminases, and creatine kinase) were assessed after 3 and 12 months. After 3 months, 14 patients in the nutraceutical group achieved their therapeutic target, whereas none of the patients in the ezetimibe group did. At 1-year follow-up, 58 patients (72.5%) of the combined therapy group (n = 86) and 14 (100%) of the nutraceutical group reached the therapeutic goal. No patients experienced important undesirable effects. In conclusion, nutraceuticals alone or in combination with ezetimibe are well tolerated and improve the lipid profile in statin-intolerant patients with coronary heart disease. Further studies are needed to assess long-term effects of nutraceuticals on mortality.
Collapse
Affiliation(s)
- Giuseppe Marazzi
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy.
| | | | - Giuseppe Campolongo
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | - Silvia Quattrino
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | - Luca Cacciotti
- Institute of Cardiology, Madre Giuseppina Vannini Hospital, Rome, Italy
| | - Maurizio Volterrani
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| | - Carlo Gaudio
- Department of Cardiovascular Sciences, Sapienza University, Rome, Italy
| | - Giuseppe Rosano
- Istituto di Ricerca a Carattere Scientifico (IRCCS) San Raffaele Pisana, Rome, Italy
| |
Collapse
|
9
|
Cacciotti L, Passaseo I, Marazzi G, Camastra G, Campolongo G, Beni S, Lupparelli F, Ansalone G. Observational study on Takotsubo-like cardiomyopathy: clinical features, diagnosis, prognosis and follow-up. BMJ Open 2012; 2:bmjopen-2012-001165. [PMID: 23065445 PMCID: PMC3488753 DOI: 10.1136/bmjopen-2012-001165] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
OBJECTIVES The present study attempts to identify appropriate elements that may contribute to clarify the broad clinical features (diagnosis, care, complication and prognosis) of Takotsubo-like cardiomyopathy for improving its management. DESIGN STUDY Observational study. SETTING Primary level of care referred to the emergency department of Vannini Hospital, Rome, Italy. PARTICIPANTS The study population consisted of 75 patients, 72 of the them were women and 3 were men with a mean age of 71.9±9.6 years. METHODS From February 2004 to November 2010, prospectively included 84 consecutive patients diagnosed for suspected Takotsubo-like cardiomyopathy. To be eligible, patients had to meet all the Mayo clinic criteria in the absence of neurological trauma or intracranial haemorrhage. Moreover, those patients that at follow-up still presented alteration of acute phase at ECG and echocardiogram were excluded. Thus, 75 patients comprised the study population. To follow-up 19 patients were lost. RESULTS None of 75 patients died in acute phase. All patients were promptly discharged (8.4±4.4 days), since they recovered their normal functional status without symptoms. Follow-up information was available for 56 patients. At a mean follow-up time of 2.2±2 years (range, 0.1-6.8 years) two octogenarian patients (2.6%) died because of sudden cardiac death and pulmonary embolism, respectively. The Takotsubo-like cardiomyopathy recurred in one patient. CONCLUSIONS The results of this study support the previous reports about the good prognosis, also in critically ill patients, of Takotsubo-like cardiomyopathy. Further assessment will be needed to determine a careful and sustained follow-up for choosing the best care and foreseeing the recurrences of this emerging condition.
Collapse
Affiliation(s)
| | | | | | | | | | - Sergio Beni
- Cardiology Unit, Madre G. Vannini Hospital, Rome, Italy
| | | | | |
Collapse
|
10
|
Affiliation(s)
- Demetrio Tallarico
- From the Department of Heart and Great Vessels “Attilio Reale,” “Sapienza,” University of Rome, Rome, Italy
| | - Pier Andrea Chiavari
- From the Department of Heart and Great Vessels “Attilio Reale,” “Sapienza,” University of Rome, Rome, Italy
| | - Giuseppe Campolongo
- From the Department of Heart and Great Vessels “Attilio Reale,” “Sapienza,” University of Rome, Rome, Italy
| |
Collapse
|
11
|
Greco C, Chiavari PA, Campolongo G, Mariani S, Messa F, Tallarico D, Schiariti M, Gonnella C, Gaudio C. Transnasal transesophageal echocardiography: a new approach for the PFO occlusion in awake patients. Catheter Cardiovasc Interv 2008; 72:538-41. [PMID: 18814237 DOI: 10.1002/ccd.21665] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVES To reduce risks, discomfort, cost, and operative time for percutaneous patent foramen ovale (PFO) closure, we propose to perform this procedure under transesophageal echo-guidance using a 10 Fr. catheter introduced through nasal way (TEENW). BACKGROUND Transesophageal or intracardiac echocardiography is commonly used to guide percutaneous PFO closure. Sedation needed quite frequently during transesophageal echocardiography, increased patients' discomfort, procedure prolongation, costs, use of both femoral veins, and additional intracardiac manipulations are the main limitations of standard techniques. METHODS We enrolled 20 consecutive patients with a history of cerebral ischemia and PFO with right-to-left shunt. In 15 patients Amplatzer PFO occluder was used, whereas in five patients with longer PFO tunnel (>10 mm) Cardia Intrasept was selected. Without sedation, a multifrequency monoplane probe, developed for intracardiac echocardiography, was introduced into the nostril and advanced forward the esophagus. Then under echo guidance, the closing device was presented, opened and released. RESULTS Procedure lasted for an average of 33.3 min, and no complications were seen. At procedure's completion, six patients showed persistence of reduced shunt during Valsalva manoeuvre. At six-month follow-up, shunts disappeared in all patients. CONCLUSION TEENW is safe and well tolerated, and images' quality is high enough to deserve widespread adoption of this technique for PFO closure.
Collapse
Affiliation(s)
- Cesare Greco
- Dept of Cuore E Grossi Vasi A. Reale, Sapienza University of Rome, Rome, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Tallarico D, Chiavari PA, Mollo P, Campolongo G, Greco C, Gaudio C. Transesophageal echocardiography through nasal way as a guide to percutaneous closure of patent foramen ovale. Echocardiography 2007; 23:790-2. [PMID: 16999701 DOI: 10.1111/j.1540-8175.2006.00313.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Percutaneous device closure of patent foramen ovale (PFO) has become an effective and safe alternative to medical or surgery treatment. Transesophageal echocardiography (TEE), as commonly used to guide this procedure, has the limitation to require general anesthesia. Recently, intracardiac echocardiography (ICE) with AcuNav probe was used to guide percutaneous PFO closure. We report a 42 year-old man with two previous cryptogenetic strokes in whom both diagnosis and guidance of PFO closure were performed by means of TEE using the AcuNav catheter introduced through nasal way (TEENW). This technique, that does not require general anesthesia, provided adequate and complete view of the Amplatzer procedure. TEENW might offer a feasible and equivalent echocardiographic alternative either to standard TEE or ICE as a guide to percutaneous PFO closure.
Collapse
Affiliation(s)
- Demetrio Tallarico
- II Division of Cardiology, Department of the Heart and Great Vessels, University La Sapienza, Via R. Zandonai 86, 00194 Rome, Italy.
| | | | | | | | | | | |
Collapse
|
13
|
Tallarico D, Chiavari PA, Campolongo G, Mollo P, Rizzo V, Marziali M. Transesophageal echocardiography through nasal way diagnoses bicuspid aortic valve. Echocardiography 2005; 22:149-50. [PMID: 15693782 DOI: 10.1111/j.0742-2822.2005.04046.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
- Demetrio Tallarico
- II Division of Cardiology, University "La Sapienza," Rome, Italy. demetrio.tallarico@uniroma1@it
| | | | | | | | | | | |
Collapse
|
14
|
Affiliation(s)
- Demetrio Tallarico
- Institute of the Heart and Large Vessels Attilio Reale, La Sapienza University of Rome, Italy.
| | | | | | | |
Collapse
|